Analysts Offer Insights on Healthcare Companies: Antares Pharma (NASDAQ: ATRS) and Galmed Pharmaceuticals (NASDAQ: GLMD)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (NASDAQ: ATRS) and Galmed Pharmaceuticals (NASDAQ: GLMD) with bullish sentiments.

Antares Pharma (NASDAQ: ATRS)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS), with a price target of $3.50. The company’s shares closed yesterday at $1.98, close to its 52-week low of $1.58.

According to TipRanks.com, Livnat is ranked 0 out of 5 stars with an average return of -8.0% and a 37.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.

Antares Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.

Galmed Pharmaceuticals (NASDAQ: GLMD)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Galmed Pharmaceuticals (NASDAQ: GLMD), with a price target of $24. The company’s shares closed yesterday at $5.45.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 23.5% and a 44.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Madrigal Pharmaceuticals Inc, and Aviragen Therapeutics Inc.

Galmed Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $24.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.